HC Wainwright Predicts Nyxoah’s Q1 Earnings (NASDAQ:NYXH)

Nyxoah S.A. (NASDAQ:NYXH) – HC Wainwright upped their Q1 2025 earnings estimates for Nyxoah in a research report issued to clients and investors on Wednesday, March 26th. HC Wainwright analyst E. White now expects that the company will post earnings of ($0.48) per share for the quarter, up from their prior estimate of ($0.50). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Nyxoah’s current full-year earnings is ($1.91) per share. HC Wainwright also issued estimates for Nyxoah’s Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($1.86) EPS and FY2027 earnings at ($0.58) EPS.

Nyxoah (NASDAQ:NYXH) last released its earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.02 million. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%.

Separately, Stifel Nicolaus dropped their target price on shares of Nyxoah from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, March 14th.

Nyxoah Trading Down 4.4 %

NYXH opened at $7.65 on Friday. The stock has a market capitalization of $260.56 million, a price-to-earnings ratio of -4.09 and a beta of 1.42. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. Nyxoah has a twelve month low of $6.76 and a twelve month high of $13.50. The company has a 50-day simple moving average of $10.35 and a 200 day simple moving average of $9.35.

Institutional Trading of Nyxoah

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its position in Nyxoah by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock valued at $137,000 after acquiring an additional 2,774 shares during the last quarter. Walleye Capital LLC boosted its stake in shares of Nyxoah by 23.9% in the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock valued at $119,000 after purchasing an additional 2,862 shares in the last quarter. Kovack Advisors Inc. grew its holdings in shares of Nyxoah by 100.0% during the 4th quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock valued at $160,000 after purchasing an additional 10,000 shares during the last quarter. LPL Financial LLC acquired a new position in Nyxoah during the 4th quarter worth approximately $102,000. Finally, Ameriprise Financial Inc. acquired a new position in Nyxoah during the 4th quarter worth approximately $135,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.